---
title: Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants
euct_id: 2023-507910-28-00
phase: Phase 1
status: Completed
sponsor: Arvinas Operations Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2023-507910-28-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2023-507910-28-00"
ctis_last_updated: "2026-04-01T03:42:18.039992531"
source: EU Clinical Trials Information System (CTIS)
---
# Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants

**EU CT Number:** [2023-507910-28-00](https://euclinicaltrials.eu/ctis-public/view/2023-507910-28-00)

## Key Facts

- **Phase:** Phase 1
- **Status:** Completed
- **Sponsor:** Arvinas Operations Inc.
- **Start Date:** 2024-01-03
- **Completion Date:** 2025-04-01
- **Conditions:** Parkinson's Disease

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Centre for Human Drug Research, Leiden, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Maximum age:** 64 Years
- **Sex:** MALE

```
Condition: Parkinson's Disease
Age groups: adults 18-64
Sex: male
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2023-507910-28-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2023-507910-28-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2023-507910-28-00*